It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The causative agent of the COVID-19 pandemic, SARS-CoV-2, is steadily mutating during continuous transmission among humans. Such mutations can occur in the spike (S) protein that binds to the ACE2 receptor and is cleaved by TMPRSS2. However, whether S mutations affect SARS-CoV-2 cell entry remains unknown. Here, we show that naturally occurring S mutations can reduce or enhance cell entry via ACE2 and TMPRSS2. A SARS-CoV-2 S-pseudotyped lentivirus exhibits substantially lower entry than that of SARS-CoV S. Among S variants, the D614G mutant shows the highest cell entry, as supported by structural and binding analyses. Nevertheless, the D614G mutation does not affect neutralization by antisera against prototypic viruses. Taken together, we conclude that the D614G mutation increases cell entry by acquiring higher affinity to ACE2 while maintaining neutralization susceptibility. Based on these findings, further worldwide surveillance is required to understand SARS-CoV-2 transmissibility among humans.
SARS-CoV-2 D614G spike protein mutation is one of the predominant circulating vital mutants. Here, Ozono et al. demonstrate that D614G mutation increases in vitro cell entry by acquiring higher affinity to ACE2.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 National Institute of Infectious Diseases, Department of Pathology, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880); University of Yamanashi, Faculty of Life and Environmental Sciences, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581)
2 National Institute of Infectious Diseases, Department of Pathology, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880)
3 National Hospital Organization Nagoya Medical Center, Clinical Research Center, Nagoya, Japan (GRID:grid.410840.9) (ISNI:0000 0004 0378 7902)
4 Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto, Japan (GRID:grid.410795.e)
5 Self-Defense Forces Central Hospital, Tokyo, Japan (GRID:grid.415474.7)
6 University of Yamanashi, Faculty of Life and Environmental Sciences, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581)
7 Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto, Japan (GRID:grid.267500.6)